Indication: Solid Tumors

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Locally Advanced or Metastatic Disease

Sub-indication: Non-small cell lung cancer (NSCLC) - squamous cell histology only; Exocrine pancreatic adenocarcinoma; Squamous cell carcinoma of the head and neck (SCCHN)

Line of Therapy: NSCLC- No more than two lines. Must have had a platinum based regimen; Pancreatic- 2nd line. Must have received gemcitabine or 5FU based regimen; • SCCHN- 2nd or 3rd line (no more than 2 systemic regimens). Must have had a platinum based therapy. If eligible must receive a CPI;

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: Seattle Genetics, Inc

Learn more at ClinicalTrials.gov

Email for more information: CancerResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.